Are you over 18 and want to see adult content?
More Annotations
A complete backup of www.rap-up.com/2020/02/27/lil-baby-my-turn-stream/
Are you over 18 and want to see adult content?
A complete backup of www.cbssports.com/nba/news/lakers-vs-pelicans-odds-line-spread-2020-nba-picks-feb-25-predictions-from-simul
Are you over 18 and want to see adult content?
A complete backup of news.now.com/home/local/player?newsId=382193
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of regatastoricavenezia.it
Are you over 18 and want to see adult content?
A complete backup of johnahartford.org
Are you over 18 and want to see adult content?
A complete backup of onepiecetower.tokyo
Are you over 18 and want to see adult content?
A complete backup of tasteofthesouthmagazine.com
Are you over 18 and want to see adult content?
A complete backup of analysisbusiness.org
Are you over 18 and want to see adult content?
Text
HOME
Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is great unmet medical need. WHO WE ARE - PHARMACYCLICS Pharmacyclics employees excel in knowledge, experience, drive and commitment to transform the treatment of cancer and other serious diseases. We recognize that each employee’s contributions are significant and play an important role in our overall mission. IMBRUVICA - PHARMACYCLICS Potential of IMBRUVICA ® We are committed to fully exploring the potential of IMBRUVICA ® and its unique mechanism of action against tumor cells and in the immune system in multiple diseases over the next 5+ years, both as a single agent and in combination with a wide variety of other therapies. CONTACT US - PHARMACYCLICS Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is a great unmet medical need. PRESS ROOM - PHARMACYCLICS Pharmacyclics is an AbbVie company based in Silicon Valley, California developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is a great unmet medical need. COMPLIANCE - PHARMACYCLICS Pharmacyclics’ ethics and compliance program (the “Program”) reflects our commitment to compliance with the laws and regulations applicable to our business, including the California Health and Safety Code §§119400-119402 (the “California Act”).MEDICAL INFORMATION
Our Medical Information portal is intended only for healthcare professionals in the United States. Through this portal, you may request information using our request form. GRANTS - PHARMACYCLICS.COM Your request must be submitted at least 45 days (PST) prior to the "decision needed by date." The decision needed by date is the date a decision on the Grant is needed by in order to plan, confirm or proceed with the program. POST MARKETING COMMITMENTS Following approval of a drug or biologic product, the U.S. Food and Drug Administration (FDA) may request and/or require the sponsoring company to conduct further studies that are designed to gather additional information about the product's safety, effectiveness,and/or optimal use.
PRESS ARTICLE
AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA ®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program. The ibrutinib clinical program is designed to fully explore the potential of this first-in-class molecule as a single or combination therapy for multiple cancers and other diseases.HOME
Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is great unmet medical need. WHO WE ARE - PHARMACYCLICS Pharmacyclics employees excel in knowledge, experience, drive and commitment to transform the treatment of cancer and other serious diseases. We recognize that each employee’s contributions are significant and play an important role in our overall mission. IMBRUVICA - PHARMACYCLICS Potential of IMBRUVICA ® We are committed to fully exploring the potential of IMBRUVICA ® and its unique mechanism of action against tumor cells and in the immune system in multiple diseases over the next 5+ years, both as a single agent and in combination with a wide variety of other therapies. CONTACT US - PHARMACYCLICS Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is a great unmet medical need. PRESS ROOM - PHARMACYCLICS Pharmacyclics is an AbbVie company based in Silicon Valley, California developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is a great unmet medical need. COMPLIANCE - PHARMACYCLICS Pharmacyclics’ ethics and compliance program (the “Program”) reflects our commitment to compliance with the laws and regulations applicable to our business, including the California Health and Safety Code §§119400-119402 (the “California Act”).MEDICAL INFORMATION
Our Medical Information portal is intended only for healthcare professionals in the United States. Through this portal, you may request information using our request form. GRANTS - PHARMACYCLICS.COM Your request must be submitted at least 45 days (PST) prior to the "decision needed by date." The decision needed by date is the date a decision on the Grant is needed by in order to plan, confirm or proceed with the program. POST MARKETING COMMITMENTS Following approval of a drug or biologic product, the U.S. Food and Drug Administration (FDA) may request and/or require the sponsoring company to conduct further studies that are designed to gather additional information about the product's safety, effectiveness,and/or optimal use.
PRESS ARTICLE
AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA ®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program. The ibrutinib clinical program is designed to fully explore the potential of this first-in-class molecule as a single or combination therapy for multiple cancers and other diseases.OUR SCIENCE
Our science extends beyond the borders of our laboratories. We work to discover new therapies to advance the standard of care and strive to help patients rediscover the Magic of Normal.PHARMACYCLICS
When used on this Web site, the words "anticipate,” "believe,” "estimate,” "expect,” "expectation,” "goal", “should,” "would,” "project,” "plan,” "predict",” "intend,” "target," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information HEALTHCARE PROFESSIONALS As your partner in care, we are here to collaborate with you to help make positive differences in the health and well-being of patients. Together, we can work to provide transformative therapies for patients with unmet medical need.AREAS OF STUDY
LYM3003, SPARKLE. LYM3003, SPARKLE, is a randomized, open-label, safety and efficacy study of ibrutinib in pediatric and young adult patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma and is set up to be conducted in two parts. SEARCH - PHARMACYCLICS Pharmacyclics LLC; 995 East Arques Avenue; Sunnyvale, California 94085; Phone: +1-408-215-3000; e-mail: info@pcyc.com; IMBRUVICA® is a registered trademark ofOUR CULTURE
A Message from Ann Tomlin . Hear from Ann Tomlin, Head of Human Resources, about our culture and guiding principles.PRIVACY POLICY
Pharmacyclics LLC; 995 East Arques Avenue; Sunnyvale, California 94085; Phone: +1-408-215-3000; e-mail: info@pcyc.com; IMBRUVICA® is a registered trademark of PRIVACY NOTICE FOR INVESTIGATORS AND OTHER SITE STAFF 2 Document Name: PCYC PRIVACY NOTICE/Investigator & Other Site Staff Version 1 8JUN2020 • all affiliates within the AbbVie group, including AbbVie Inc. located in U.S. as our parent company,PRESS ARTICLE
NORTH CHICAGO, Ill., May 9, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) updated the IMBRUVICA® (ibrutinib) Prescribing Information (PI) to include new data from two Phase 3 trials supporting its expanded use in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma רתאה תווצב םירחא םידבוע רובעו םירקוח רובע תויטרפ תרהצה 1 ם ירתאה תווצב םירחא םידבועו םירקוח םלועה ראש תויטרפ תרהצה pcyc :ךמסמ םש ינויב 8 הסרג HOME MEDICAL INFORMATIONCONTACT US Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is great unmet medical need. WHO WE ARE - PHARMACYCLICS Pharmacyclics employees excel in knowledge, experience, drive and commitment to transform the treatment of cancer and other serious diseases. We recognize that each employee’s contributions are significant and play an important role in our overall mission. IMBRUVICA - PHARMACYCLICS Potential of IMBRUVICA ® We are committed to fully exploring the potential of IMBRUVICA ® and its unique mechanism of action against tumor cells and in the immune system in multiple diseases over the next 5+ years, both as a single agent and in combination with a wide variety of other therapies. CONTACT US - PHARMACYCLICS Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is a great unmet medical need. PRESS ROOM - PHARMACYCLICS Pharmacyclics is an AbbVie company based in Silicon Valley, California developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is a great unmet medical need. COMPLIANCE - PHARMACYCLICS Pharmacyclics’ ethics and compliance program (the “Program”) reflects our commitment to compliance with the laws and regulations applicable to our business, including the California Health and Safety Code §§119400-119402 (the “California Act”).MEDICAL INFORMATION
Our Medical Information portal is intended only for healthcare professionals in the United States. Through this portal, you may request information using our request form. GRANTS - PHARMACYCLICS.COM Your request must be submitted at least 45 days (PST) prior to the "decision needed by date." The decision needed by date is the date a decision on the Grant is needed by in order to plan, confirm or proceed with the program. POST MARKETING COMMITMENTS Following approval of a drug or biologic product, the U.S. Food and Drug Administration (FDA) may request and/or require the sponsoring company to conduct further studies that are designed to gather additional information about the product's safety, effectiveness,and/or optimal use.
PRESS ARTICLE
AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA ®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program. The ibrutinib clinical program is designed to fully explore the potential of this first-in-class molecule as a single or combination therapy for multiple cancers and other diseases. HOME MEDICAL INFORMATIONCONTACT US Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is great unmet medical need. WHO WE ARE - PHARMACYCLICS Pharmacyclics employees excel in knowledge, experience, drive and commitment to transform the treatment of cancer and other serious diseases. We recognize that each employee’s contributions are significant and play an important role in our overall mission. IMBRUVICA - PHARMACYCLICS Potential of IMBRUVICA ® We are committed to fully exploring the potential of IMBRUVICA ® and its unique mechanism of action against tumor cells and in the immune system in multiple diseases over the next 5+ years, both as a single agent and in combination with a wide variety of other therapies. CONTACT US - PHARMACYCLICS Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is a great unmet medical need. PRESS ROOM - PHARMACYCLICS Pharmacyclics is an AbbVie company based in Silicon Valley, California developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is a great unmet medical need. COMPLIANCE - PHARMACYCLICS Pharmacyclics’ ethics and compliance program (the “Program”) reflects our commitment to compliance with the laws and regulations applicable to our business, including the California Health and Safety Code §§119400-119402 (the “California Act”).MEDICAL INFORMATION
Our Medical Information portal is intended only for healthcare professionals in the United States. Through this portal, you may request information using our request form. GRANTS - PHARMACYCLICS.COM Your request must be submitted at least 45 days (PST) prior to the "decision needed by date." The decision needed by date is the date a decision on the Grant is needed by in order to plan, confirm or proceed with the program. POST MARKETING COMMITMENTS Following approval of a drug or biologic product, the U.S. Food and Drug Administration (FDA) may request and/or require the sponsoring company to conduct further studies that are designed to gather additional information about the product's safety, effectiveness,and/or optimal use.
PRESS ARTICLE
AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA ®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program. The ibrutinib clinical program is designed to fully explore the potential of this first-in-class molecule as a single or combination therapy for multiple cancers and other diseases.OUR SCIENCE
Our science extends beyond the borders of our laboratories. We work to discover new therapies to advance the standard of care and strive to help patients rediscover the Magic of Normal.PHARMACYCLICS
When used on this Web site, the words "anticipate,” "believe,” "estimate,” "expect,” "expectation,” "goal", “should,” "would,” "project,” "plan,” "predict",” "intend,” "target," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information HEALTHCARE PROFESSIONALS As your partner in care, we are here to collaborate with you to help make positive differences in the health and well-being of patients. Together, we can work to provide transformative therapies for patients with unmet medical need.AREAS OF STUDY
LYM3003, SPARKLE. LYM3003, SPARKLE, is a randomized, open-label, safety and efficacy study of ibrutinib in pediatric and young adult patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma and is set up to be conducted in two parts. SEARCH - PHARMACYCLICS Pharmacyclics LLC; 995 East Arques Avenue; Sunnyvale, California 94085; Phone: +1-408-215-3000; e-mail: info@pcyc.com; IMBRUVICA® is a registered trademark ofOUR CULTURE
A Message from Ann Tomlin . Hear from Ann Tomlin, Head of Human Resources, about our culture and guiding principles.PRIVACY POLICY
Pharmacyclics LLC; 995 East Arques Avenue; Sunnyvale, California 94085; Phone: +1-408-215-3000; e-mail: info@pcyc.com; IMBRUVICA® is a registered trademark of PRIVACY NOTICE FOR INVESTIGATORS AND OTHER SITE STAFF 2 Document Name: PCYC PRIVACY NOTICE/Investigator & Other Site Staff Version 1 8JUN2020 • all affiliates within the AbbVie group, including AbbVie Inc. located in U.S. as our parent company,PRESS ARTICLE
NORTH CHICAGO, Ill., May 9, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) updated the IMBRUVICA® (ibrutinib) Prescribing Information (PI) to include new data from two Phase 3 trials supporting its expanded use in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma רתאה תווצב םירחא םידבוע רובעו םירקוח רובע תויטרפ תרהצה 1 ם ירתאה תווצב םירחא םידבועו םירקוח םלועה ראש תויטרפ תרהצה pcyc :ךמסמ םש ינויב 8 הסרג HOME MEDICAL INFORMATIONCONTACT US Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is great unmet medical need. WHO WE ARE - PHARMACYCLICS Pharmacyclics employees excel in knowledge, experience, drive and commitment to transform the treatment of cancer and other serious diseases. We recognize that each employee’s contributions are significant and play an important role in our overall mission. IMBRUVICA - PHARMACYCLICS Potential of IMBRUVICA ® We are committed to fully exploring the potential of IMBRUVICA ® and its unique mechanism of action against tumor cells and in the immune system in multiple diseases over the next 5+ years, both as a single agent and in combination with a wide variety of other therapies. CONTACT US - PHARMACYCLICS Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is a great unmet medical need.OUR SCIENCE
Our science extends beyond the borders of our laboratories. We work to discover new therapies to advance the standard of care and strive to help patients rediscover the Magic of Normal. COMPLIANCE - PHARMACYCLICS Pharmacyclics’ ethics and compliance program (the “Program”) reflects our commitment to compliance with the laws and regulations applicable to our business, including the California Health and Safety Code §§119400-119402 (the “California Act”).MEDICAL INFORMATION
Our Medical Information portal is intended only for healthcare professionals in the United States. Through this portal, you may request information using our request form. HEALTHCARE PROFESSIONALS As your partner in care, we are here to collaborate with you to help make positive differences in the health and well-being of patients. Together, we can work to provide transformative therapies for patients with unmet medical need.OUR CULTURE
A Message from Ann Tomlin . Hear from Ann Tomlin, Head of Human Resources, about our culture and guiding principles. POST MARKETING COMMITMENTS Following approval of a drug or biologic product, the U.S. Food and Drug Administration (FDA) may request and/or require the sponsoring company to conduct further studies that are designed to gather additional information about the product's safety, effectiveness,and/or optimal use.
HOME MEDICAL INFORMATIONCONTACT US Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is great unmet medical need. WHO WE ARE - PHARMACYCLICS Pharmacyclics employees excel in knowledge, experience, drive and commitment to transform the treatment of cancer and other serious diseases. We recognize that each employee’s contributions are significant and play an important role in our overall mission. IMBRUVICA - PHARMACYCLICS Potential of IMBRUVICA ® We are committed to fully exploring the potential of IMBRUVICA ® and its unique mechanism of action against tumor cells and in the immune system in multiple diseases over the next 5+ years, both as a single agent and in combination with a wide variety of other therapies. CONTACT US - PHARMACYCLICS Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is a great unmet medical need.OUR SCIENCE
Our science extends beyond the borders of our laboratories. We work to discover new therapies to advance the standard of care and strive to help patients rediscover the Magic of Normal. COMPLIANCE - PHARMACYCLICS Pharmacyclics’ ethics and compliance program (the “Program”) reflects our commitment to compliance with the laws and regulations applicable to our business, including the California Health and Safety Code §§119400-119402 (the “California Act”).MEDICAL INFORMATION
Our Medical Information portal is intended only for healthcare professionals in the United States. Through this portal, you may request information using our request form. HEALTHCARE PROFESSIONALS As your partner in care, we are here to collaborate with you to help make positive differences in the health and well-being of patients. Together, we can work to provide transformative therapies for patients with unmet medical need.OUR CULTURE
A Message from Ann Tomlin . Hear from Ann Tomlin, Head of Human Resources, about our culture and guiding principles. POST MARKETING COMMITMENTS Following approval of a drug or biologic product, the U.S. Food and Drug Administration (FDA) may request and/or require the sponsoring company to conduct further studies that are designed to gather additional information about the product's safety, effectiveness,and/or optimal use.
HEALTHCARE PROFESSIONALS As your partner in care, we are here to collaborate with you to help make positive differences in the health and well-being of patients. Together, we can work to provide transformative therapies for patients with unmet medical need.AREAS OF STUDY
LYM3003, SPARKLE. LYM3003, SPARKLE, is a randomized, open-label, safety and efficacy study of ibrutinib in pediatric and young adult patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma and is set up to be conducted in two parts.PHARMACYCLICS
When used on this Web site, the words "anticipate,” "believe,” "estimate,” "expect,” "expectation,” "goal", “should,” "would,” "project,” "plan,” "predict",” "intend,” "target," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information SEARCH - PHARMACYCLICS Pharmacyclics LLC; 995 East Arques Avenue; Sunnyvale, California 94085; Phone: +1-408-215-3000; e-mail: info@pcyc.com; IMBRUVICA® is a registered trademark of GRANTS - PHARMACYCLICS.COM Your request must be submitted at least 45 days (PST) prior to the "decision needed by date." The decision needed by date is the date a decision on the Grant is needed by in order to plan, confirm or proceed with the program.PRIVACY POLICY
Pharmacyclics LLC; 995 East Arques Avenue; Sunnyvale, California 94085; Phone: +1-408-215-3000; e-mail: info@pcyc.com; IMBRUVICA® is a registered trademark of PRIVACY NOTICE FOR INVESTIGATORS AND OTHER SITE STAFF 2 Document Name: PCYC PRIVACY NOTICE/Investigator & Other Site Staff Version 1 8JUN2020 • all affiliates within the AbbVie group, including AbbVie Inc. located in U.S. as our parent company,PRESS ARTICLE
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA ® (ibrutinib) in Combination with Obinutuzumab (GAZYVA ®) for Previously Untreated Chronic Lymphocytic Leukemia (CLL). If granted, IMBRUVICA plus obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the FDA for first-line CLL treatmentPRESS ARTICLE
AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA ®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program. The ibrutinib clinical program is designed to fully explore the potential of this first-in-class molecule as a single or combination therapy for multiple cancers and other diseases. רתאה תווצב םירחא םידבוע רובעו םירקוח רובע תויטרפ תרהצה 1 ם ירתאה תווצב םירחא םידבועו םירקוח םלועה ראש תויטרפ תרהצה pcyc :ךמסמ םש ינויב 8 הסרג HOME MEDICAL INFORMATIONCONTACT US Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is great unmet medical need. WHO WE ARE - PHARMACYCLICS Pharmacyclics employees excel in knowledge, experience, drive and commitment to transform the treatment of cancer and other serious diseases. We recognize that each employee’s contributions are significant and play an important role in our overall mission. IMBRUVICA - PHARMACYCLICS Potential of IMBRUVICA ® We are committed to fully exploring the potential of IMBRUVICA ® and its unique mechanism of action against tumor cells and in the immune system in multiple diseases over the next 5+ years, both as a single agent and in combination with a wide variety of other therapies. CONTACT US - PHARMACYCLICS Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is a great unmet medical need.OUR SCIENCE
Our science extends beyond the borders of our laboratories. We work to discover new therapies to advance the standard of care and strive to help patients rediscover the Magic of Normal. COMPLIANCE - PHARMACYCLICS Pharmacyclics’ ethics and compliance program (the “Program”) reflects our commitment to compliance with the laws and regulations applicable to our business, including the California Health and Safety Code §§119400-119402 (the “California Act”).MEDICAL INFORMATION
Our Medical Information portal is intended only for healthcare professionals in the United States. Through this portal, you may request information using our request form. HEALTHCARE PROFESSIONALS As your partner in care, we are here to collaborate with you to help make positive differences in the health and well-being of patients. Together, we can work to provide transformative therapies for patients with unmet medical need.OUR CULTURE
A Message from Ann Tomlin . Hear from Ann Tomlin, Head of Human Resources, about our culture and guiding principles. POST MARKETING COMMITMENTS Following approval of a drug or biologic product, the U.S. Food and Drug Administration (FDA) may request and/or require the sponsoring company to conduct further studies that are designed to gather additional information about the product's safety, effectiveness,and/or optimal use.
HOME MEDICAL INFORMATIONCONTACT US Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is great unmet medical need. WHO WE ARE - PHARMACYCLICS Pharmacyclics employees excel in knowledge, experience, drive and commitment to transform the treatment of cancer and other serious diseases. We recognize that each employee’s contributions are significant and play an important role in our overall mission. IMBRUVICA - PHARMACYCLICS Potential of IMBRUVICA ® We are committed to fully exploring the potential of IMBRUVICA ® and its unique mechanism of action against tumor cells and in the immune system in multiple diseases over the next 5+ years, both as a single agent and in combination with a wide variety of other therapies. CONTACT US - PHARMACYCLICS Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is a great unmet medical need.OUR SCIENCE
Our science extends beyond the borders of our laboratories. We work to discover new therapies to advance the standard of care and strive to help patients rediscover the Magic of Normal. COMPLIANCE - PHARMACYCLICS Pharmacyclics’ ethics and compliance program (the “Program”) reflects our commitment to compliance with the laws and regulations applicable to our business, including the California Health and Safety Code §§119400-119402 (the “California Act”).MEDICAL INFORMATION
Our Medical Information portal is intended only for healthcare professionals in the United States. Through this portal, you may request information using our request form. HEALTHCARE PROFESSIONALS As your partner in care, we are here to collaborate with you to help make positive differences in the health and well-being of patients. Together, we can work to provide transformative therapies for patients with unmet medical need.OUR CULTURE
A Message from Ann Tomlin . Hear from Ann Tomlin, Head of Human Resources, about our culture and guiding principles. POST MARKETING COMMITMENTS Following approval of a drug or biologic product, the U.S. Food and Drug Administration (FDA) may request and/or require the sponsoring company to conduct further studies that are designed to gather additional information about the product's safety, effectiveness,and/or optimal use.
HEALTHCARE PROFESSIONALS As your partner in care, we are here to collaborate with you to help make positive differences in the health and well-being of patients. Together, we can work to provide transformative therapies for patients with unmet medical need.AREAS OF STUDY
LYM3003, SPARKLE. LYM3003, SPARKLE, is a randomized, open-label, safety and efficacy study of ibrutinib in pediatric and young adult patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma and is set up to be conducted in two parts.PHARMACYCLICS
When used on this Web site, the words "anticipate,” "believe,” "estimate,” "expect,” "expectation,” "goal", “should,” "would,” "project,” "plan,” "predict",” "intend,” "target," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information SEARCH - PHARMACYCLICS Pharmacyclics LLC; 995 East Arques Avenue; Sunnyvale, California 94085; Phone: +1-408-215-3000; e-mail: info@pcyc.com; IMBRUVICA® is a registered trademark of GRANTS - PHARMACYCLICS.COM Your request must be submitted at least 45 days (PST) prior to the "decision needed by date." The decision needed by date is the date a decision on the Grant is needed by in order to plan, confirm or proceed with the program.PRIVACY POLICY
Pharmacyclics LLC; 995 East Arques Avenue; Sunnyvale, California 94085; Phone: +1-408-215-3000; e-mail: info@pcyc.com; IMBRUVICA® is a registered trademark of PRIVACY NOTICE FOR INVESTIGATORS AND OTHER SITE STAFF 2 Document Name: PCYC PRIVACY NOTICE/Investigator & Other Site Staff Version 1 8JUN2020 • all affiliates within the AbbVie group, including AbbVie Inc. located in U.S. as our parent company,PRESS ARTICLE
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA ® (ibrutinib) in Combination with Obinutuzumab (GAZYVA ®) for Previously Untreated Chronic Lymphocytic Leukemia (CLL). If granted, IMBRUVICA plus obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the FDA for first-line CLL treatmentPRESS ARTICLE
AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA ®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program. The ibrutinib clinical program is designed to fully explore the potential of this first-in-class molecule as a single or combination therapy for multiple cancers and other diseases. רתאה תווצב םירחא םידבוע רובעו םירקוח רובע תויטרפ תרהצה 1 ם ירתאה תווצב םירחא םידבועו םירקוח םלועה ראש תויטרפ תרהצה pcyc :ךמסמ םש ינויב 8 הסרג HOME MEDICAL INFORMATIONCONTACT US Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is great unmet medical need. WHO WE ARE - PHARMACYCLICS Pharmacyclics employees excel in knowledge, experience, drive and commitment to transform the treatment of cancer and other serious diseases. We recognize that each employee’s contributions are significant and play an important role in our overall mission. IMBRUVICA - PHARMACYCLICS Potential of IMBRUVICA ® We are committed to fully exploring the potential of IMBRUVICA ® and its unique mechanism of action against tumor cells and in the immune system in multiple diseases over the next 5+ years, both as a single agent and in combination with a wide variety of other therapies. CONTACT US - PHARMACYCLICS Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is a great unmet medical need.OUR SCIENCE
Our science extends beyond the borders of our laboratories. We work to discover new therapies to advance the standard of care and strive to help patients rediscover the Magic of Normal. COMPLIANCE - PHARMACYCLICS Pharmacyclics’ ethics and compliance program (the “Program”) reflects our commitment to compliance with the laws and regulations applicable to our business, including the California Health and Safety Code §§119400-119402 (the “California Act”).MEDICAL INFORMATION
Our Medical Information portal is intended only for healthcare professionals in the United States. Through this portal, you may request information using our request form. HEALTHCARE PROFESSIONALS As your partner in care, we are here to collaborate with you to help make positive differences in the health and well-being of patients. Together, we can work to provide transformative therapies for patients with unmet medical need.OUR CULTURE
A Message from Ann Tomlin . Hear from Ann Tomlin, Head of Human Resources, about our culture and guiding principles. POST MARKETING COMMITMENTS Following approval of a drug or biologic product, the U.S. Food and Drug Administration (FDA) may request and/or require the sponsoring company to conduct further studies that are designed to gather additional information about the product's safety, effectiveness,and/or optimal use.
HOME MEDICAL INFORMATIONCONTACT US Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is great unmet medical need. WHO WE ARE - PHARMACYCLICS Pharmacyclics employees excel in knowledge, experience, drive and commitment to transform the treatment of cancer and other serious diseases. We recognize that each employee’s contributions are significant and play an important role in our overall mission. IMBRUVICA - PHARMACYCLICS Potential of IMBRUVICA ® We are committed to fully exploring the potential of IMBRUVICA ® and its unique mechanism of action against tumor cells and in the immune system in multiple diseases over the next 5+ years, both as a single agent and in combination with a wide variety of other therapies. CONTACT US - PHARMACYCLICS Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is a great unmet medical need.OUR SCIENCE
Our science extends beyond the borders of our laboratories. We work to discover new therapies to advance the standard of care and strive to help patients rediscover the Magic of Normal. COMPLIANCE - PHARMACYCLICS Pharmacyclics’ ethics and compliance program (the “Program”) reflects our commitment to compliance with the laws and regulations applicable to our business, including the California Health and Safety Code §§119400-119402 (the “California Act”).MEDICAL INFORMATION
Our Medical Information portal is intended only for healthcare professionals in the United States. Through this portal, you may request information using our request form. HEALTHCARE PROFESSIONALS As your partner in care, we are here to collaborate with you to help make positive differences in the health and well-being of patients. Together, we can work to provide transformative therapies for patients with unmet medical need.OUR CULTURE
A Message from Ann Tomlin . Hear from Ann Tomlin, Head of Human Resources, about our culture and guiding principles. POST MARKETING COMMITMENTS Following approval of a drug or biologic product, the U.S. Food and Drug Administration (FDA) may request and/or require the sponsoring company to conduct further studies that are designed to gather additional information about the product's safety, effectiveness,and/or optimal use.
HEALTHCARE PROFESSIONALS As your partner in care, we are here to collaborate with you to help make positive differences in the health and well-being of patients. Together, we can work to provide transformative therapies for patients with unmet medical need.AREAS OF STUDY
LYM3003, SPARKLE. LYM3003, SPARKLE, is a randomized, open-label, safety and efficacy study of ibrutinib in pediatric and young adult patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma and is set up to be conducted in two parts.PHARMACYCLICS
When used on this Web site, the words "anticipate,” "believe,” "estimate,” "expect,” "expectation,” "goal", “should,” "would,” "project,” "plan,” "predict",” "intend,” "target," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information SEARCH - PHARMACYCLICS Pharmacyclics LLC; 995 East Arques Avenue; Sunnyvale, California 94085; Phone: +1-408-215-3000; e-mail: info@pcyc.com; IMBRUVICA® is a registered trademark of GRANTS - PHARMACYCLICS.COM Your request must be submitted at least 45 days (PST) prior to the "decision needed by date." The decision needed by date is the date a decision on the Grant is needed by in order to plan, confirm or proceed with the program.PRIVACY POLICY
Pharmacyclics LLC; 995 East Arques Avenue; Sunnyvale, California 94085; Phone: +1-408-215-3000; e-mail: info@pcyc.com; IMBRUVICA® is a registered trademark of PRIVACY NOTICE FOR INVESTIGATORS AND OTHER SITE STAFF 2 Document Name: PCYC PRIVACY NOTICE/Investigator & Other Site Staff Version 1 8JUN2020 • all affiliates within the AbbVie group, including AbbVie Inc. located in U.S. as our parent company,PRESS ARTICLE
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA ® (ibrutinib) in Combination with Obinutuzumab (GAZYVA ®) for Previously Untreated Chronic Lymphocytic Leukemia (CLL). If granted, IMBRUVICA plus obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the FDA for first-line CLL treatmentPRESS ARTICLE
AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA ®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program. The ibrutinib clinical program is designed to fully explore the potential of this first-in-class molecule as a single or combination therapy for multiple cancers and other diseases. רתאה תווצב םירחא םידבוע רובעו םירקוח רובע תויטרפ תרהצה 1 ם ירתאה תווצב םירחא םידבועו םירקוח םלועה ראש תויטרפ תרהצה pcyc :ךמסמ םש ינויב 8 הסרג*
*
* Careers
* Press Room
* Contact Us
* Who We Are
* Our Culture
* History
* Compliance
* Our Approach
* IMBRUVICA®
* Patient Support
* Post Marketing Commitments * Disease Areas of Focus * Mechanism of Action* Our Science
* Areas of Study
* Healthcare Professionals * Medical Information * Investigator-Sponsored Trials * Patient Support Program* Grants
* Privacy Policies
* Privacy Policies IIS Collab*
Striving to Bring Back The Magic of Normal Patient-first. Science-based. Employee-driven.*
Striving to Bring Back The Magic of Normal Patient-first. Science-based. Employee-driven.*
Striving to Bring Back The Magic of Normal Patient-first. Science-based. Employee-driven.* Who We Are
* Our Culture
* History
* Compliance
* Our Approach
* IMBRUVICA®
* Patient Support
* Post Marketing Commitments * Disease Areas of Focus * Mechanism of Action* Our Science
* Areas of Study
* Healthcare Professionals * Medical Information * Investigator-Sponsored Trials * Patient Support Program* Grants
* Privacy Policies
* Privacy Policies IIS Collab Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is great unmet medical need. We seek to discover innovative therapies to improve standards of care and strive to help our patients REDISCOVER THE MAGIC OF NORMAL.×
* Home
* Who We Are
* Our Culture
* History
* Compliance
* Our Approach
* IMBRUVICA®
* Patient Support
* Post Marketing Commitments * Disease Areas of Focus * Mechanism of Action* Our Science
* Areas of Study
* Healthcare Professionals * Medical Information * Investigator-Sponsored Trials * Patient Support Program* Grants
* Privacy Policies
* Privacy Policies IIS Collab*
*
* Terms of Use
* Privacy Policy
* Pharmacyclics LLC
* 999 East Arques Avenue * Sunnyvale, California 94085 * Phone: +1-408-774-0330 * Fax: +1-408-215-3689 * e-mail: info@pcyc.com IMBRUVICA® is a registered trademark of Pharmacyclics LLC 2017 Pharmacyclics LLC All rights reserved.Our Culture
At Pharmacyclics, our patients motivate and inspire us to push the boundaries of science. We strive to make a difference in their lives. It’s not only our mission, but our passion. IMBRUVICA® (ibrutinib) For more information on IMBRUVICA® (ibrutinib), a Bruton's tyrosine kinase (BTK) inhibitor, please visit:www.imbruvica.com
Join the Team
Visit our Careers page to learn about our Mode of Action and the exciting opportunities available at Pharmacyclics, an AbbVie company.*
*
* Who We Are
* Our Approach
* Our Science
* Press Room
* Terms of Use
* Privacy Policy
* Pharmacyclics LLC
* 995 East Arques Avenue * Sunnyvale, California 94085 * Phone: +1-408-215-3000 * e-mail: info@pcyc.com IMBRUVICA® is a registered trademark of Pharmacyclics LLC 2020 Pharmacyclics LLC All rights reserved.CCRC-04226 04/20
Contact Us
Contact form successfully sent!* Pharmacyclics LLC
* 995 East Arques Avenue * Sunnyvale, California 94085 * Phone: +1-408-215-3000 * e-mail: info@pcyc.com IMBRUVICA® is a registered trademark of Pharmacyclics LLC 2020 Pharmacyclics LLC All rights reserved.CCRC-04226 04/20
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0